Cargando…
Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
PURPOSE: Esophageal squamous cell carcinoma is associated with high morbidity and mortality rate for which radiotherapy is the main treatment modality. Niraparib, a Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) was previously reported to confer radiosensitivity in different malignancies includin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283188/ https://www.ncbi.nlm.nih.gov/pubmed/35364771 http://dx.doi.org/10.1007/s12094-022-02818-7 |
_version_ | 1784747279955001344 |
---|---|
author | Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng |
author_facet | Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng |
author_sort | Cui, Yuzhong |
collection | PubMed |
description | PURPOSE: Esophageal squamous cell carcinoma is associated with high morbidity and mortality rate for which radiotherapy is the main treatment modality. Niraparib, a Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) was previously reported to confer radiosensitivity in different malignancies including non-small cell lung cancer. In this study, we assessed the in vivo ability of niraparib in conferring radiosensitivity to esophageal squamous cell carcinoma cells. MATERIALS AND METHODS: In this study, KYSE-30 and KYSE-150 cell lines were selected as in vivo esophageal squamous cell carcinoma models. The experimental groups were: niraparib tosylate alone, radiotherapy alone, control (no intervention), and combination therapy (radiotherapy + niraparib tosylate). Cell cytotoxicity assay, colony formation assay, flow cytometry, immunofluorescence, Western blotting, immunohistochemistry, lentivirus transfection analysis, and xenograft models were used for confirming radiosensitizing ability of niraparib and to investigate the possible cellular mechanism involved in radiosensitization. RESULTS: The colony formation efficiency of the combination group was significantly much lower than that of the single radiation group (P < 0.01). Cell cytotoxicity assay demonstrated a significant reduction in proliferation of irradiated cells after treatment with niraparib tosylate compared to niraparib tosylate alone (P < 0.01). Cell apoptosis significantly increased in the combination group compared to either niraparib tosylate or radiotherapy alone (P < 0.01). Rate of tumor suppression rate was significantly high in the combined treatment group (P < 0.01) but, significantly decreased in nude mice. Western blot and lentivirus infection model suggested overexpression of FANCG genes to confer radiosensitivity. CONCLUSION: These results suggest that the synergistic effect of niraparib tosylate and radiation may be related to the down-regulation of FANCG. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12094-022-02818-7. |
format | Online Article Text |
id | pubmed-9283188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92831882022-07-16 Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng Clin Transl Oncol Research Article PURPOSE: Esophageal squamous cell carcinoma is associated with high morbidity and mortality rate for which radiotherapy is the main treatment modality. Niraparib, a Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) was previously reported to confer radiosensitivity in different malignancies including non-small cell lung cancer. In this study, we assessed the in vivo ability of niraparib in conferring radiosensitivity to esophageal squamous cell carcinoma cells. MATERIALS AND METHODS: In this study, KYSE-30 and KYSE-150 cell lines were selected as in vivo esophageal squamous cell carcinoma models. The experimental groups were: niraparib tosylate alone, radiotherapy alone, control (no intervention), and combination therapy (radiotherapy + niraparib tosylate). Cell cytotoxicity assay, colony formation assay, flow cytometry, immunofluorescence, Western blotting, immunohistochemistry, lentivirus transfection analysis, and xenograft models were used for confirming radiosensitizing ability of niraparib and to investigate the possible cellular mechanism involved in radiosensitization. RESULTS: The colony formation efficiency of the combination group was significantly much lower than that of the single radiation group (P < 0.01). Cell cytotoxicity assay demonstrated a significant reduction in proliferation of irradiated cells after treatment with niraparib tosylate compared to niraparib tosylate alone (P < 0.01). Cell apoptosis significantly increased in the combination group compared to either niraparib tosylate or radiotherapy alone (P < 0.01). Rate of tumor suppression rate was significantly high in the combined treatment group (P < 0.01) but, significantly decreased in nude mice. Western blot and lentivirus infection model suggested overexpression of FANCG genes to confer radiosensitivity. CONCLUSION: These results suggest that the synergistic effect of niraparib tosylate and radiation may be related to the down-regulation of FANCG. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12094-022-02818-7. Springer International Publishing 2022-04-01 2022 /pmc/articles/PMC9283188/ /pubmed/35364771 http://dx.doi.org/10.1007/s12094-022-02818-7 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
title | Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
title_full | Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
title_fullStr | Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
title_full_unstemmed | Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
title_short | Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
title_sort | therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283188/ https://www.ncbi.nlm.nih.gov/pubmed/35364771 http://dx.doi.org/10.1007/s12094-022-02818-7 |
work_keys_str_mv | AT cuiyuzhong therapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT huangwei therapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT dufeng therapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT yinxiaoyang therapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT fenglei therapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT libaosheng therapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy |